Nektar Therapeutics
NKTRHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Nektar Therapeutics focuses on Biotechnology services and products. Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. At a $1.98B market cap, Nektar Therapeutics ranks as a small-cap company within healthcare. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma.
Market Cap
$1.98B
Beta
1.25
P/E (TTM)
—
P/E (Fwd)
-4.66
EPS (TTM)
$-7.93
EPS (Fwd)
$-12.56
ROE
-53.6%
ROA
-15.3%
Cash
$568.6M
Total Debt
$143.4M
Free CF
-$107.2M
52W Change
420.5%
Annual Financials
Cash vs Debt
Nektar Therapeutics holds $568.6M in cash against $143.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$107.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -53.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $92.1M (2022) to $55.2M (2025), a 40% decline worth watching.
With cash comfortably exceeding debt, NKTR has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Nektar Therapeutics's trajectory.